Preference, satisfaction and critical errors with Genuair and Breezhaler inhalers in patients with COPD: a randomised, cross-over, multicentre study.
BACKGROUND
The specific attributes of inhaler devices can influence patient use, satisfaction and treatment compliance, and may ultimately impact on clinical outcomes in patients with chronic obstructive pulmonary disease (COPD).


OBJECTIVE
To assess patient preference, satisfaction and critical inhaler technique errors with Genuair (a multidose inhaler) and Breezhaler (a single-dose inhaler) after 2 weeks of daily use.


METHODS
Patients with COPD and moderate to severe airflow obstruction were randomised in a cross-over, open-label, multicentre study to consecutive once-daily inhalations of placebo via Genuair and Breezhaler, in addition to current COPD medication. The primary end point was the proportion of patients who preferred Genuair versus Breezhaler after 2 weeks (Patient Satisfaction and Preference Questionnaire). Other end points included overall satisfaction and correct use of the inhalers after 2 weeks, and willingness to continue with each device.


RESULTS
Of the 128 patients enrolled, 127 were included in the safety population (male n=91; mean age 67.6 years). Of the 110 of the 123 patients in the intent-to-treat population who indicated an inhaler preference, statistically significantly more patients preferred Genuair than Breezhaler (72.7 vs. 27.3%; P<0.001). Mean overall satisfaction scores were also greater for Genuair than for Breezhaler (5.9 vs. 5.3, respectively; P<0.001). After 2 weeks, there was no statistically significant difference in the number of patients who made ⩾1 critical inhaler technique error with Breezhaler than with Genuair (7.3 vs. 3.3%, respectively).


CONCLUSIONS
Patient overall preference and satisfaction was significantly higher with Genuair compared with Breezhaler. The proportion of patients making critical inhaler technique errors was low with Genuair and Breezhaler.
Hospital del Mar-IMIM, CIBERES, Barcelona, Spain.
Sergi
S
Pascual
Pneumologie Odeonsplatz, Munich, Germany.
Jan
J
Feimer
1] Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK [2] Department of Respiratory Medicine, Freeman Hospital, Newcastle upon Tyne, UK.
Anthony
A
De Soyza
1] Servicio de Neumología, Hospital Universitari Son Espases, Palma de Mallorca, Spain [2] Institut d'Investigació Sanitària de Palma (IdISPa), Palma de Mallorca, Spain [3] CIBERES, Instituto Carlos III, Madrid, Spain.
Jaume
J
Sauleda Roig
Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, UK.
John
J
Haughney
Medical Affairs, Almirall, Barcelona, Spain.
Laura
L
Padullés
1] R&D Centre, AstraZeneca, Barcelona, Spain [2] Formerly of Almirall S.A., Barcelona, Spain.
Beatriz
B
Seoane
Forest Research Institute, a subsidiary of Actavis PLC, Jersey City, NJ, USA.
Ludmyla
L
Rekeda
1] R&D Centre, AstraZeneca, Barcelona, Spain [2] Formerly of Almirall S.A., Barcelona, Spain.
Anna
A
Ribera
Department of Pharmacy, University of Huddersfield, Huddersfield, UK.
Henry
H
Chrystyn
D000368:Aged; D018592:Cross-Over Studies; D004867:Equipment Design; D004868:Equipment Failure / Q000706:statistics & numerical data*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009330:Nebulizers and Vaporizers / Q000706:statistics & numerical data; D017060:Patient Satisfaction; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy*; D019141:Respiratory System Agents / Q000008:administration & dosage
D019141:Respiratory System Agents